title: Naptumomab estafenatox: a new immunoconjugate.
abstract: BACKGROUND
  New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.
  
  
  METHODS
  This review examines the preclinical and the published clinical data with regards to naptumomab.
  
  
  RESULTS
  This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent.
  
  
  CONCLUSIONS
  Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
authors.affiliation: Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.
authors.forename: Matthew K
authors.initials: MK
authors.lastname: Robinson
authors.forename: R Katherine
authors.initials: RK
authors.lastname: Alpaugh
authors.forename: Hossein
authors.initials: H
authors.lastname: Borghaei
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D004768:Enterotoxins / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004768:Enterotoxins; D018796:Immunoconjugates; C543500:naptumomab estafenatox